[{"_1":2,"_131":-5,"_132":-5},"loaderData",{"_3":4,"_9":10},"root",{"_5":6,"_7":8},"locale","id","isCms",false,"routes/tags/$slug",{"_11":12,"_13":14,"_15":16,"_118":119,"_125":121,"_129":124,"_130":-5},"slug","anhui-loncom-china","ads",[],"posts",[17],{"_6":18,"_19":20,"_11":21,"_22":23,"_24":25,"_26":27,"_28":29,"_30":31,"_32":33,"_34":35,"_36":37,"_38":39,"_40":41,"_42":43,"_44":20,"_45":46,"_47":48,"_49":50,"_51":20,"_52":53,"_54":55,"_56":57,"_58":59,"_115":116,"_68":117},"019bb76a-d997-7362-9cfd-0fcae0f9f069","title","COVID-19 – Vaksin Zifivax buatan China siap diproduksi di Indonesia","covid-19-vaksin-zifivax-buatan-china-siap-diproduksi-di-indonesia","main_id","019bb73f-28ac-70ed-836a-68ade28a117a","main_name","Nasional","main_slug","nasional","date","2022-01-11 12:01:22","author_id","019bb745-b426-73a2-9a49-5ddcb6765ea0","author_name","indowin","full_name","Indonesia Window","author_firstname","Indonesia","author_slug","indonesiawindow","content","Jakarta (Indonesia Window) – Vaksin Zifivax telah mendapat izin penggunaan darurat atau Emergency Use Authorization (EUA) sebagai vaksin booster (penguat) dari Badan Pengawas Obat dan Makanan (BPOM) pada Senin (10/1).

Zifivax merupakan vaksin yang dikembangkan dan diproduksi oleh perusahaan asal China, Anhui Zhifei Longcom Biopharmaceutical, dengan platform rekombinan protein sub-unit.

Vaksin Zifivax akan dikembangkan dan diproduksi di Indonesia melalui kolaborasi produksi antara PT Jakarta Biopharmaceutical Industry dan PT Biotis Pharmaceutical Indonesia, kata Direktur Pemasaran dan Kemitraan PT Jakarta Biopharmaceutical Industry (JBio) Chairuddin Yunus yang dikonfirmasi di Jakarta, Senin (10/1).

Sementara itu, Direktur operasional PT Biotis Pharmaceuticals Indonesia (Biotis), Rakesh Deoddut Vyas, mengatakan vaksin Zifivax telah siap diproduksi fill and finished di pabrik PT Biotis yang berlokasi di Gunung Sindur, Kabupaten Bogor, Jawa Barat.

Rakesh mengatakan persiapan produksi PT Biotis sudah rampung setelah lima bulan terakhir secara intensif melakukan kerja sama dengan PT JBio dan Anhui Loncom China.

\"Kami sudah mulai melakukan transfer teknologi dengan Anhui sejak lima bulan lalu. Semua protokol operasi kualitas dan produksi serta handling transfer bulk vaksin Zifivax telah dipersiapkan dengan matang,\" katanya.

Dia mengatakan Anhui dalam waktu dekat akan mengirimkan sembilan orang tenaga ahli pengawas kualitas dan produksi untuk membantu tim Biotis dan JBio dalam proses alih teknologi untuk produksi vaksin Zifivax dapat dilakukan di Indonesia.

Menurut Rakesh, proses produksi fill and finished atau barang jadi gelombang pertama sudah dapat dilakukan pada pekan terakhir Januari 2022.

Target produksi secara komersial akan dimulai pertengahan Februari 2022 dengan kapasitas fill and finished PT Biotis saat ini sekitar 30 juta dosis per bulan atau 360 juta dosis per tahun.

\"Kapasitas ini akan terus kami tingkatkan sejalan dengan rencana produksi vaksin COVID-19 platform inactivated Merah Putih hasil kerja sama dengan Unair (Universitas Airlangga), yang akan dilakukan sekitar bulan Juni/Juli dan Agustus 2022,\" katanya.

Laporan: Redaksi","excerpt","Jakarta (Indonesia Window) – Vaksin Zifivax telah mendapat izin penggunaan darurat atau Emergency Use Authorization (EUA) sebagai vaksin booster (penguat) dari...","seo_kw","seo_title","","seo_description","Proses produksi fill and finished atau barang jadi gelombang pertama vaksin Zifivax sudah dapat dilakukan pada pekan terakhir Januari 2022.","image","2022/01/mat-napo-kQrBavaF-Fk-unsplash-scaled.jpg","image_alt","image_caption","Ilustrasi. (Mat Napo on Unsplash)","image_url","https://indonesiawindow.sgp1.cdn.digitaloceanspaces.com/2022/01/mat-napo-kQrBavaF-Fk-unsplash-scaled.jpg","status","publish","tags",[60,76,83,90,96,103,110],{"_6":61,"_62":63,"_64":65,"_11":66,"_49":-5,"_67":-5,"_68":69,"_70":69,"_71":72},"019bb744-1c2f-71ec-b547-aa3d474813de","old_id",2509,"name","vaksin Merah Putih Indonesia","vaksin-merah-putih-indonesia","description","created_at","2026-01-13T12:10:52.000000Z","updated_at","pivot",{"_73":18,"_74":61,"_68":75,"_70":75},"post_id","tag_id","2026-01-13T12:53:11.000000Z",{"_6":77,"_62":78,"_64":79,"_11":80,"_49":-5,"_67":-5,"_68":81,"_70":81,"_71":82},"019bb744-6b86-72e0-8705-57b4c0b5956f",9825,"Emergency Use Authorization","emergency-use-authorization","2026-01-13T12:11:13.000000Z",{"_73":18,"_74":77,"_68":75,"_70":75},{"_6":84,"_62":85,"_64":86,"_11":87,"_49":-5,"_67":-5,"_68":88,"_70":88,"_71":89},"019bb744-6fa7-71be-85d6-8ef75b1c6c58",10305,"Biotis Pharmaceutical Indonesia","biotis-pharmaceutical-indonesia","2026-01-13T12:11:14.000000Z",{"_73":18,"_74":84,"_68":75,"_70":75},{"_6":91,"_62":92,"_64":93,"_11":94,"_49":-5,"_67":-5,"_68":88,"_70":88,"_71":95},"019bb744-7243-737f-b94f-d520a44f437d",10607,"vaksin covid-19 yang disetujui BPOM","vaksin-covid-19-yang-disetujui-bpom",{"_73":18,"_74":91,"_68":75,"_70":75},{"_6":97,"_62":98,"_64":99,"_11":100,"_49":-5,"_67":-5,"_68":101,"_70":101,"_71":102},"019bb744-74fb-7132-88f2-b2a0edf5beef",10959,"vaksin covid-19 Zifivax","vaksin-covid-19-zifivax","2026-01-13T12:11:15.000000Z",{"_73":18,"_74":97,"_68":75,"_70":75},{"_6":104,"_62":105,"_64":106,"_11":107,"_49":-5,"_67":-5,"_68":108,"_70":108,"_71":109},"019bb744-87fa-72c5-b771-cd83846eb655",12817,"Jakarta Biopharmaceutical Industry","jakarta-biopharmaceutical-industry","2026-01-13T12:11:20.000000Z",{"_73":18,"_74":104,"_68":75,"_70":75},{"_6":111,"_62":112,"_64":113,"_11":12,"_49":-5,"_67":-5,"_68":108,"_70":108,"_71":114},"019bb744-8800-709e-89c0-6fc35366a1b3",12819,"Anhui Loncom China",{"_73":18,"_74":111,"_68":75,"_70":75},"comments",[],"2022-01-11","pagination",{"_120":121,"_122":121,"_123":124,"_125":121,"_126":121,"_127":128},"count",1,"total","perPage",12,"currentPage","totalPages","links",{},"pageSize","error","actionData","errors"]